BMRN

BioMarin Pharmaceutical Inc

Add to Watchlist

Advanced Chart

57.330

-2.13(-3.582%)1D

Overview
Forecast
Valuation
Earnings

Line

Candle

YTD

High

60.090

Open

59.310

VWAP

57.63

Vol

3.52M

Mkt Cap

11.01B

Low

56.360

Amount

203.04M

EV/EBITDA(TTM)

11.15

Total Shares

189.88M

10.17B

EV/OCF(TTM)

13.27

P/S(TTM)

3.68

BioMarin Pharmaceutical Inc. is a global biotechnology company engaged in the development of genetic discovery into medicines that make an impact on the life of each patient. The Company has eight commercial therapies and a clinical and preclinical pipeline. Its commercial products include Vimizim (elosulfase alpha), Naglazyme (galsulfase), Palynziq (pegvaliase-pqpz), Brineura (cerliponase alfa), Aldurazyme (laronidase), Roctavian (valoctocogene roxaparvovec), Kuvan (sapropterin dihydrochloride), and Voxzogo (vosoritide). Vimizim is an enzyme replacement therapy for the treatment of MPS IVA, a lysosomal storage disorder. The Roctavian is an adeno-associated virus (AAV5) vector gene therapy designed to restore factor VIII plasma concentrations in patients with severe hemophilia A. Its key clinical programs include Vosoritide, BMN 333, BMN 390, BMN 351, BMN 349, and INZ-701. Its late-stage enzyme replacement therapy, INZ-701, is being developed for the treatment of ENPP1 deficiency.

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2026Q1

FY2025Q4

FY2025Q3

828.21M

+11.15%

1.260

+11.5%

815.44M

+9.12%

0.961

+4.42%

790.04M

+5.94%

0.824

-9.49%

Estimates Revision

The market is revising Upward the revenue expectations for BioMarin Pharmaceutical Inc. (BMRN) for FY2025, with the revenue forecasts being adjusted by 0.15% over the past three months. During the same period, the stock price has changed by -6.58%.

Revenue Estimates for FY2025

Revise Upward

+0.15%

In Past 3 Month

EPS Estimates for FY2025

Revise Downward

-2.94%

In Past 3 Month

Stock Price

Go Down

-6.58%

In Past 3 Month

23 Analyst Rating

70.07% Upside

Wall Street analysts forecast BMRN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BMRN is 97.50 USD with a low forecast of 69.00 USD and a high forecast of 122.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

19 Buy

4 Hold

0 Sell

Strong Buy

70.07% Upside

Current: 57.330

Low

69.00

Averages

97.50

High

122.00

70.07% Upside

Current: 57.330

Low

69.00

Averages

97.50

High

122.00

UBS

Buy

maintain

$113 -> $114

2025-08-05

Reason

UBS

Price Target

$113 -> $114

2025-08-05

maintain

Buy

Reason

UBS raised the firm's price target on BioMarin to $114 from $113 and keeps a Buy rating on the shares.

Morgan Stanley

Overweight

downgrade

$97 -> $96

2025-07-22

Reason

Morgan Stanley

Price Target

$97 -> $96

2025-07-22

downgrade

Overweight

Reason

Morgan Stanley lowered the firm's price target on BioMarin to $96 from $97 and keeps an Overweight rating on the shares. The firm notes in an earnings preview that for Q2 its estimates are in line with the Street on revenues, but further out its sees BioMarin having under-appreciated revenue potential.

JPMorgan

NULL -> Overweight

maintain

$108 -> $113

2025-07-14

Reason

JPMorgan

Price Target

$108 -> $113

2025-07-14

maintain

NULL -> Overweight

Reason

JPMorgan raised the firm's price target on BioMarin to $113 from $108 and keeps an Overweight rating on the shares. The firm adjusted the company's model ahead of the Q2 report.

Morgan Stanley

Overweight

downgrade

$105 -> $97

2025-07-03

Reason

Morgan Stanley

Price Target

$105 -> $97

2025-07-03

downgrade

Overweight

Reason

Morgan Stanley assumed coverage of BioMarin with an Overweight rating with a price target of $97, down from $105. BioMarin is trading at a 10-year low, more than adequately reflecting risk to its Voxzogo franchise, the analyst says. Morgan Stanley believes the potential opportunity in other patient populations and the company's pipeline may be underappreciated by the Street.

Oppenheimer

Leland Gershell

Hold

Buy

Upgrades

$98

2025-02-24

Reason

Oppenheimer

Leland Gershell

Price Target

$98

2025-02-24

Upgrades

Hold

Buy

Reason

Oppenheimer upgraded BioMarin to Outperform from Perform with a $98 price target.

Scotiabank

George Farmer

Hold

Maintains

$78 → $80

2025-02-20

Reason

Scotiabank

George Farmer

Price Target

$78 → $80

2025-02-20

Maintains

Hold

Reason

Scotiabank raised the firm's price target on BioMarin to $80 from $78 and keeps a Sector Perform rating on the shares. The firm is raising its price target on the stock following a Q4 Voxzogo beat and bullish 2025 revenue outlook, the analyst tells investors. Scotiabank, however, maintains its rating due to concerns about the potential competitive threats to the Voxzogo franchise.

See All Ratings

Valuation Metrics

The current forward P/E ratio for BioMarin Pharmaceutical Inc (BMRN.O) is 13.20, compared to its 5-year average forward P/E of 44.57. For a more detailed relative valuation and DCF analysis to assess BioMarin Pharmaceutical Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

Undervalued

5Y Average PE

44.57

Current PE

13.20

Overvalued PE

69.54

Undervalued PE

19.59

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

77.17

Current EV/EBITDA

10.00

Overvalued EV/EBITDA

197.96

Undervalued EV/EBITDA

-43.61

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

Strongly Undervalued

5Y Average PS

6.55

Current PS

3.36

Overvalued PS

8.03

Undervalued PS

5.06

Financials

Annual

Quarterly

FY2025Q2

YoY :

+15.92%

825.41M

Total Revenue

FY2025Q2

YoY :

+73.62%

276.89M

Operating Profit

FY2025Q2

YoY :

+124.43%

240.53M

Net Income after Tax

FY2025Q2

YoY :

+123.64%

1.23

EPS - Diluted

FY2025Q2

YoY :

+73.23%

167.90M

Free Cash Flow

FY2025Q2

YoY :

+1.96%

81.23

Gross Profit Margin - %

FY2025Q2

YoY :

+174.45%

22.56

FCF Margin - %

FY2025Q2

YoY :

+93.62%

29.14

Net Margin - %

FY2025Q2

YoY :

+130.63%

10.24

ROIC

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

216.3K

USD

6-9

Months

91.9K

USD

0-12

Months

350.3K

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

0-3

Months

0.0

Volume

3-6

Months

0.0

Volume

6-9

Months

652.4K

Volume

0-12

Months

0.0

Volume

Bought

0-3

0.0

Volume

Months

3-6

422.4K

Volume

Months

6-9

2.7M

Volume

Months

0-12

0.0

Volume

Months

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

216.3K

USD

6-9

Months

91.9K

USD

0-12

Months

350.3K

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

BMRN News & Events

Events Timeline

2025-08-04 (ET)

2025-08-04

16:07:10

BioMarin raises FY25 adjusted EPS view to $4.40-$4.55 from $4.20-$4.40

2025-08-04

16:05:02

BioMarin reports Q2 adjusted EPS $1.44, consensus $1.01

2025-06-24 (ET)

2025-06-24

09:02:37

BioMarin reports new data underscoring the long-term efficacy of ROCTAVIAN

News

9.5

08-05Benzinga

BioMarin Discontinues Preclinical Drug Candidate, Advances BMN 333 Toward 2030

2.0

08-05NASDAQ.COM

BMRN Makes Bullish Cross Above Critical Moving Average

4.0

08-05TipRanks

3 Best Stocks to Buy Now, 8/5/2025, According to Top Analysts

People Also Watch

Stifel Financial Corp

Aurora Innovation Inc

6.160

USD

-0.65%

FAQ

What is BioMarin Pharmaceutical Inc (BMRN) stock price today?

The current price of BMRN is 57.33 USD — it has decreased -3.58 % in the last trading day.

BMRN

Market Estimates

Valuation Metrics

Forward PE

Forward EV/EBITDA

Forward PS

Financials

Trading Trends

BMRN News & Events

Events Timeline

News

People Also Watch

FAQ

What is BioMarin Pharmaceutical Inc (BMRN) stock price today?

What is BioMarin Pharmaceutical Inc (BMRN)'s business?

What is the price predicton of BMRN Stock?

What is BioMarin Pharmaceutical Inc (BMRN)'s revenue for the last quarter?

What is BioMarin Pharmaceutical Inc (BMRN)'s earnings per share (EPS) for the last quarter?

What changes have occurred in the market's expectations for BioMarin Pharmaceutical Inc (BMRN)'s fundamentals?

How many employees does BioMarin Pharmaceutical Inc (BMRN). have?

What is BioMarin Pharmaceutical Inc (BMRN) market cap?